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Abstract: The maintenance of patients with renal transplant typically involves two or more
drugs to prevent rejection and prolong graft survival. The calcineurin inhibitors (CNI) are the
most commonly recommended medicines in combinations with others. While immunosuppressive
treatment regimens are well established, there is insufficient long-term effectiveness data to help
guide future management decisions. The study analyzes the effectiveness of treatment regimens
containing CNI after renal transplantation during 16 years of follow-up with real-world data from
the Brazilian National Health System (SUS). This was a retrospective study of 2318 SUS patients
after renal transplantion. Patients were propensity score-matched (1:1) by sex, age, type and year of
transplantation. Kaplan–Meier analysis was used to estimate the cumulative probabilities of survival.
A Cox proportional hazard model was used to evaluate factors associated with progression to graft
loss. Multivariable analysis, adjusted for diabetes mellitus and race/color, showed a greater risk
of graft loss for patients using tacrolimus plus mycophenolate compared to patients treated with
cyclosporine plus azathioprine. In conclusion, this Brazilian real-world study, with a long follow-up
period using matched analysis for relevant clinical features and the representativeness of the sample,
demonstrated improved long-term effectiveness for therapeutic regimens containing cyclosporine
plus azathioprine. Consequently, we recommend that protocols and clinical guidelines for renal
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transplantation should consider the cyclosporine plus azathioprine regimen as a potential first line
option, along with others.
Keywords: real-world data; real-world evidence; renal transplantation; immunosuppressants; graft
survival; effectiveness; tacrolimus; cyclosporine; clinical epidemiology
1. Introduction
Kidney transplantation is considered the optimal choice for the treatment of patients with advanced
renal failure due to improved quality of life and life expectancy versus renal dialysis, and it is also the
most cost-effective option when compared to dialysis [1–6]. The Brazilian National Health System
(Sistema Único de Saúde (SUS)) performs more than 95% of all kidney transplants in the country and
guarantees access to immunosuppressants for transplant patients without co-payment [7,8].
In line with international guidelines [9,10], the recommended maintenance immunosuppression in
Brazil consists of a triple regimen containing a corticosteroid, a calcineurin inhibitor (CNI) (cyclosporine
or tacrolimus) and an antiproliferative agent (azathioprine or mycophenolate). Alternatively, either of
the two latter drug classes may be replaced by the mammalian target of rapamycin (mTOR), sirolimus
or everolimus, depending on the patient’s clinical characteristics [8,11].
Different results regarding the effectiveness and safety among possible immunosuppressive
regimes have been reported in multiple studies [7,12–14]. With respect to tacrolimus and cyclosporine,
considered as key elements of any immunosuppressive regimen, a variety of studies compared their
relative effectiveness and safety. A systematic review has not shown differences between tacrolimus
and cyclosporine at one and five years of graft survival [15], as well as mortality. However, another
systematic review has shown has tacrolimus is superior to cyclosporine in relation to graft loss and
overall efficiency [16]. Similar controversies exist in relation to the anti-proliferatives [10] as well as
with sirolimus and everolimus [14,16,17]. This illustrates the fact that recommendations for the use of
different immunosuppressive regimens are complex and influenced by the type of donor and other
clinical factors including prior dialysis length of time, recipient age, and sex [7,18].
Previous real-world studies conducted in Brazil comparing patient outcomes with cyclosporine
versus tacrolimus in association with any other immunosuppressant at five [18] and 10-years
follow-up [7] showed a clinical benefit favoring cyclosporine. However, considering that the
recommended treatment typically consists of a triple regimen, and that time is a fundamental
factor in any survival analysis, there is still doubt about which immunosuppressive regimen is the
most effective in maintaining renal grafts over a longer time. This is important especially if there
are appreciable cost differences between these immunosuppressants as currently seen in Brazil [7].
Consequently, this long-term study was undertaken to deepen our understanding of potential treatment
approaches for patients undergoing renal transplantation in Brazil, especially given the heterogeneity
of the population and concerns with the results of short-term follow-up studies. As a result, we can
provide additional information to the Brazilian Ministry of Health, as well as to health professionals and
patients, regarding potential immunosuppressant choices containing either cyclosporine or tacrolimus
over 15 years of follow-up.
2. Materials and Methods
2.1. Study Design
This non-concurrent open cohort study included all patients who underwent kidney
transplantation (living donors or deceased donors) at transplantation centers throughout Brazil.
The cohort was developed through deterministic-probabilistic matching of the following administrative
databases: SUS Hospital Information System (SIH/SUS), SUS Ambulatory Information System (SIA/SUS)
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and Mortality Information System (SIM), similar to previous studies undertaken in Brazil [7,19,20].
Notification regarding mortality (SIM) is mandatory in Brazil, and immunosuppressive treatment is
dispensed monthly for patients in SUS (SIA/SUS) without any co-payment. Dialysis is recorded in the
same way as immunosuppressive therapy.
The study cohort consisted of SUS patients who underwent kidney transplants and received
immunosuppressive regimens containing either cyclosporine (Anatomical Therapeutic Chemical (ATC)
code: L04AD01) or tacrolimus (L04AD02) between 1 January 2000 and 31 December 2014. Patients were
subsequently followed up from 1 January 2001 to 31 December 2015. The entry period was established
to ensure a minimum follow-up of 12 months. The date of entry into the cohort corresponded to the
date of the transplant registered in SIH/SUS. Patients younger than 18 years and patients who died
between the first and the sixth month after transplantation were excluded as this could be related to
the surgical procedure and not to a lack of effectiveness of maintenance immunosuppressive drugs,
which is in line with previous studies [4,7,18].
The therapeutic regimen was defined as the first regimen the patient was treated with a duration of
at least 90 days (intention to treat—ITT). The following regimens were considered, stratified by the use of
cyclosporine or tacrolimus: monotherapy, concomitant use of azathioprine (L04AX01), mycophenolate
(L04AA06), everolimus (L04AA18) or sirolimus (L04AA10). Any other immunosuppressant regimens
used by patients were grouped in the category ‘other regimens’. All patients were considered to have
concomitant corticosteroids.
The patients were matched according to propensity score matching 1:1 (one-to-one). This was
established by the type of transplant, sex, age in years at the time of transplantation, and year of
transplantation, among patients prescribed either cyclosporine or tacrolimus. When more than one
individual in any group was a therapeutic candidate for pairing by the four variables, pair allocation
was randomly selected.
2.2. Event
The event used for the survival analysis was graft loss, defined as the need for dialysis for more than
three months without the concomitant use of immunosuppressive medication, re-transplantation or
death. The effectiveness of the immunosuppressive medicines was measured by means of graft survival
data. The date of the event was defined as the date of return to dialysis, the date of re-transplantation,
or the date of death, whichever occurred first. Censorship was characterized as loss of follow-up,
adopting the date of the last record referring to immunosuppression, or the end of follow-up (right
censoring). Right censoring was defined as not observing the event of interest until the end of study,
i.e, any individual that did not have an event until 31 December 2015 was censured.
2.3. Statistical Analysis
Descriptive statistical analysis of all variables in this study was performed; that is, the frequency
distribution for categorical variables and central tendency for continuous variables. The variables
included: (a) the geographic region of the hospital where the transplant was performed; (b) the calendar
year of transplantation, categorized as transplants between 2000 to 2003, 2004 to 2007, 2008 to 2011 and
2012 to 2014; (c) the sex of the recipient; (d) the age at the time of transplantation; (e) the skin color/race
of the patient; (f) the primary diagnosis of renal disease; (g) the type of transplant received (donor
alive or deceased) and (h) the dialysis period prior to renal transplantation.
The cumulative probability of graft survival at 15 years according to the therapeutic regimen was
assessed by the Kaplan–Meier estimator, and survival distributions were compared using the log-rank
test. Factors influencing graft survival were assessed initially by univariate analysis of each variable
and its association with graft loss. Variables with p < 0.20 in the univariate analysis and variables
considered clinically relevant were included in the multivariable model. The relative risk of progression
to the event adjusted for the multivariable model was calculated by the Cox proportional hazards
model and was considered as a 95% confidence interval (95% CI). The adequacy of the multivariable
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model was evaluated by the residue analysis. In order to evaluate the impact of death on graft survival,
an analysis of graft loss censored for death, i.e., considering only the return to dialysis as an event,
was also performed. In view of comparison between the regimens, we also performed an analysis of
patient death with a functional graft.
Statistical analysis was performed using the program R, version 4.3.1 (R Foundation for Statistical
Computing, Vienna, Austria) and SPSS, version 17 (SPSS Inc., Chicago, IL, USA) and a significance
level of 5% was considered.
2.4. Ethical Aspects
The Ethics Committee of the Federal University of Minas Gerais in Brazil approved this study
(number 1072253/2015).
3. Results
3.1. Patient Characteristics and Survival Rates
From January 2000 until December 2015, 3729 (23%) patients were prescribed a cyclosporine based
immunosuppressive regimen and 12,259 (77%) patients were prescribed a tacrolimus based regimen.
A total of 1159 pairs were combined by type of transplantation, sex, age and year of transplantation
between the cyclosporine and tacrolimus groups. The distribution of the number of patients receiving
each regimen within the cyclosporine or tacrolimus group is shown in Figure 1.
Of the 2318 patients included in the study, most (63.0%) were prescribed mycophenolate in
combination with a CNI, followed by azathioprine (29.0%). Only 3% of the study population were
prescribed regimens with sirolimus (1.3%) or everolimus (1.7%). In the tacrolimus group, the majority
(75.0%) of the patients were prescribed tacrolimus plus mycophenolate in combination, followed
by a tacrolimus plus azathioprine combination (18.8%). In the cyclosporine group, the cyclosporine
plus mycophenolate combination was used by half the patients (50.8%) and the cyclosporine plus
azathioprine combination by 40.0% of the study patients. The other regimens represented less than
10.0% of patients in both groups (Figure 1).
Most of the patients were male (63.2%), who declared themselves to be white/caucasian (55.0%) and
with a median age of 43 years. The main etiology of chronic renal failure was hypertension/cardiovascular
disease (19.2%). Most transplants occurred in the southeast region of Brazil (60.9%), followed by the
southern region (23.3%). The most common type of transplantation was from a living donor (63.7%)
and the median dialysis time before a transplant was 26 months (interquartile interval: 13 to 53 months).
During the follow-up, there were 421 graft losses (18.2%) which included graft losses due to death
(13.8% of the population), return to dialysis for more than three months (4.0%) and re-transplantation
(0.4%). There was also 1897 (81.8%) censures (Table 1).
The effectiveness of the different therapeutic regimens is shown in Table 2. Of the 421 (18.2%) graft
losses that occurred, 61% were related to patients who were prescribed a mycophenolate associated
regimen, 35.2% of whom were prescribed a mycophenolate plus tacrolimus combination and 25.8%
mycophenolate plus cyclosporine. The cyclosporine regimen in combination with azathioprine
demonstrated a 25.0% protection in the univariate analysis (p = 0.04). The other combinations did
not present statistically noticeable differences. Patients who were prescribed the cyclosporine plus
azathioprine regimen had a 54.0% survival (95% CI = 43.9 to 66.4) at 15 years of follow-up, whereas
patients who were prescribed tacrolimus plus azathioprine had a survival rate of 37.3% (95% CI = 21.5
to 64.6). Mycophenolate regimens showed similar survival rates (Table 2).
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Table 1. Demographic characteristics of study patients (Brazil, 2000–2015; n = 2318).
Characteristic
All Patients Cyclosporine Group Tacrolimus Group
(n = 2318) (n = 1159) (n = 1159)
n % % %
Geographic origin
Southeast 1370 59.1 25.2 33.9
South 534 23.0 15.6 7.4
Northeast 237 10.2 5.5 4.7
Midwest 134 5.8 2.8 2.9
North 43 1.9 0.9 1.0
Year of transplantation
2000–2003 592 25.5 12.8 12.8
2004–2007 592 25.5 12.8 12.8
2008–2011 720 31.1 15.5 15.5
2012–2014 414 17.9 8.9 8.9
Recipient sex
Female 852 36.8 18.4 18.4
Male 1466 63.2 31.6 31.6
Age group, years
18–25 224 9.7 4.8 4.8
26–35 530 22.9 11.4 11.4
36–45 594 25.6 12.8 12.8
46–55 580 25.0 12.5 12.5
56–65 316 13.6 6.8 6.8
>65 74 3.2 1.6 1.6
Patient skin color a
White 312 55.0 23.1 31.9
Brown 178 31.4 23.1 18.7
Black 34 6.0 1.2 4.8
Others 43 7.6 3.9 3.7
Primary cause of chronic kidney disease
Hypertension/cardiovascular disease 444 19.2 9.2 10.9
Nephritis b 199 8.6 3.0 3.3
Organ failure or rejection 52 2.2 1.2 1.1
Diabetes mellitus 67 2.9 1.4 1.5
Kidney cystic disease/neoplasms /tumors 30 1.3 0.9 0.3
Uropathies 33 1.4 0.8 0.6
Infections/other causes/undetermined 1493 64.4 31.2 33.2
Donor type
Living 1476 63.7 36.3 36.3
Deceased 842 36.3 18.2 18.2
Dialysis time before transplant, months a, c
≤26 1050 50.7 25.8 24.9
>26 1023 49.3 24.6 24.7
Events
Censoring d 1897 81.8 41.0 40.9
Graft loss 421 18.2 9.0 9.1
Death 320 13.8 7.2 6.6
Dialysis for more than 3 months 93 4.0 1.7 2.3
Re-transplant 8 0.4 0.2 0.2
a Refers to individuals with valid data. b Glomerulonephritis/interstitial nephritis/pyelonephritis. c Median
time = 26 months. d Lost to follow-up or right censoring (end of follow-up).
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Figure 1. Study flowchart (Brazil, 2000–2015; n = 2318).
Patient graft survival in the paired cohort was 50.1% (95% CI = 43.0 to 58.3) at the end of 15 years
of follow-up. Individuals in the cyclosporine group had a graft survival of 52.1% (95% CI = 44.7 to
60.8) at the end of 15 years follow-up, and patients in the tacrolimus group had a survival of 47.5%
(95% CI = 36.1 to 62.7) (Table 3). The annual graft survival probabilities observed for each group over
the 15-year period are presented in Table 3.
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Table 2. Outcome measures of effectiveness of the study patients in a matched cohort (Brazil, 2000 to
2015; n = 2318).
Variable
Graft Loss (%)
All Patients Death Dialysis for More than ThreeMonths/Re-Transplant
421 (18.2%) 320 (13.8%) 101 (4.4%)
Immunosuppressive
Regimen
Cyclosporine
Group
Tacrolimus
Group
Cyclosporine
Group
Tacrolimus
Group
Cyclosporine
Group
Tacrolimus
Group
Azathioprine 3.3 2.1 2.7 1.6 0.6 0.4
Mycophenolate 4.7 6.4 3.9 4.4 0.8 1.9
Monotherapy 0.7 0.4 0.5 0.3 0.2 0.1
Everolimus 0.1 0.0 0.1 0.0 0.0 0.0
Sirolimus 0.1 0.3 0.1 0.2 0.0 0.1
Other schemes 0.1 0.0 0.0 0.0 0.1 0.0
Total group 9.0 9.2 7.2 6.6 1.9 2.5
Hazard Ratio a (HR) Estimates for Graft Failure in Each Group Studied Survival b (95% Confidence Interval)
Immunosuppressive
Regimen
Cyclosporine Group Tacrolimus Group Cyclosporine
Group
Tacrolimus
GroupHR (95% CI) p HR (95% CI) p
Total 52.1 (44.7, 60.8) 47.5 (36.1, 62.7)
Azathioprine 0.75 (0.57, 0.99) 0.04 1.06 (0.78, 1.43) 0.68 54.0 (43.9, 66.4) 37.3 (21.5, 64.6)
Mycophenolate 1.30 (0.98, 1.71) 0.10 0.88 (0,65, 1,18) 0.39 60.9 (51.9, 71.5) 60.9 (52.1, 71.1)
Monotherapy 0.85 (0.51, 1.39) 0.50 1.28 (0.66, 2.47) 0.48 67.7 (54.8, 83.7) 51.4 (29.8, 88.9)
Everolimus c 0.97 (0.24, 3.95) 0.97 NA 57.1 (24.3, 100.0) * NA
Sirolimus 1.42 (0.35, 5.72) 0.62 2.02 (0.94, 4.18) 0.06 40,0 (29.7, 93.5) * 50.5 (28.0, 90.8) *
Note: a Result of the univariate analysis; b Survival graft survival rate at the end of 15 years of follow-up. NA: not
possible to estimate, due to the small number of patients; c incorporated in SUS in 2008; * Regimen that did not have
15 years of observation.
Table 3. Annual graft survival rates of the study patients according to the calcineurin inhibitor group
in a matched cohort (Brazil, 2000 to 2015; n = 2318).
Follow-Up Year
Graft Survival Rates (95% CI)
All Patients n = 2318 Cyclosporine Group n = 1159 Tacrolimus Group n = 1159
1st 99.2 (98.9, 99.6) 99.6 (99.2, 99.9) 98.9 (98.3, 99.5)
2nd 96.2 (95.4, 97.0) 96.7 (95.6, 97.8) 95.8 (94.6, 97.0)
3rd 93.5 (92.5, 94.6) 93.3 (91.8, 94.9) 93.8 (92.3, 95.2)
4th 90.4 (89.1, 91.7) 89.9 (88.0, 91.8) 90.9 (89.1, 92.7)
5th 87.4 (85.9, 88.9) 87.0 (84.8, 89.2) 87.3 (85.2, 89.6)
6th 83.5 (81.7, 85.3) 83.5 (80.9, 86.1) 83.5 (81.0, 86.1)
7th 79.9 (77.8, 82.0) 80.4 (77.5, 83.4) 79.4 (76.5, 82.5)
8th 74.9 (72.4, 77.5) 74.8 (71.2, 78.5) 75.0 (71.6, 78.6)
9th 71.4 (68.6, 74.3) 70.4 (66.3, 74.7) 71.9 (68.1, 75.9)
10th 67.2 (64.0, 70.6) 66.7 (62.1, 71.6) 67.7 (63.2, 72.5)
11th 64.1 (60.5, 68.0) 61.8 (56.4, 67.7) 64.7 (59.0, 69.7)
12th 59.1 (54.9, 63.7) 59.1 (53.2, 65.6) 57.1 (50.9, 64.2)
13th 55.1 (50.3, 60.3) 56.6 (50.2, 63.9) 56.0 (49.6, 63.3)
14th 52.9 (47.4, 58.9) 54.1 (47.2, 62.0) 53.5 (45.9, 62.3)
15th 50.1 (43.0, 58.3) 52.1 (44.7, 60.8) 47.5 (36.1, 62.7)
CI: confidence interval.
3.2. Factors Associated with Graft Loss
3.2.1. Univariate Analysis
Univariate analysis indicated an increased risk of graft loss for each additional year of age of the
recipient (HR = 1.03 (95% CI = 1.02 to 1.03)), an increased risk of graft loss among patients who had
a dialysis time of more than 26 months and among those who were transplanted at an earlier time
period between 2000 and 2003 (HR = 1.49 (95% CI = 1.21 to 1.83)).
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Patients who received a deceased donor organ also had a higher risk of graft loss (HR = 1.77
(95% CI = 1.46 to 2.16)), and similarly, those with diabetes (HR = 1.49 (95% CI = 1.24 to 1.80))
or hypertension/cardiovascular disease (HR = 1.32 (95% CI = 1.06 to 1.66)) as the main cause of
chronic kidney disease (CKD). Patients of color/black were also at higher risk of graft loss (HR = 3.09
(95% CI = 1.47 to 6.46)). The graphical representation of the survival rates according to these variables
is shown in Figure 2.Int. J. Environ. Res. Public Health 2020, 17, x 10 of 16 
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3.2.2. Multivariable Analysis
Considering the level of statistical significance used in the univariate analysis (p < 0.20) and the
relevant epidemiological clinical data, multivariable analyses were performed. Since the race/color of
patients has an appreciable impact on graft survival, but information on this variable is missing for a
large proportion of the study population (Table 1), two additional multivariable models were considered.
A multivariable analysis including all patients revealed that the following variables were associated
with a higher risk of graft loss: patients who had a dialysis length of time longer than 26 months before
transplantation (HR= 1:53 (95% CI = 1.25 to 1.88)), as well as patients with a diagnosis of diabetes
mellitus (HR = 2.55 (95% CI = 1.55 to 3.71)) and hypertension/cardiovascular diseases (HR = 1.28
(95% CI = 1.102 to 1.61)) as the primary cause of CKD (Table 4).
Table 4. Hazard ratios for graft loss according to Cox logistic regression of a 15-year follow-up (Brazil
2000–2015; n = 2318).
Variable HR (95% CI) p-Value
Primary cause of chronic kidney disease
Diabetes mellitus 2.55 (1.55, 3.71) <0.01
Hypertension/cardiovascular diseases 1.28 (1.02, 1.61) 0.033
Dialysis length of time before transplant (>26 months) 1.53 (1.25, 1.88) <0.01
HR: hazard ratio; CI: confidence interval.
The multivariable analysis also demonstrated that a greater risk of graft loss was associated
with patients diagnosed with diabetes mellitus as the main cause of CKD (HR = 3.14 (95% CI = 1.11
to 8.81)), patients who declared their race/color as black (HR = 2.61 (95% CI = 1.13 to 6.02)) and
patients prescribed tacrolimus plus mycophenolate (HR = 2.17 (95% CI = 1.02 to 2.41)) compared to a
cyclosporine plus azathioprine regimen (Table 5).
Table 5. Hazard ratios for graft loss according to Cox logistic regression of a 15-year follow-up
considering patient race/color (Brazil, 2000–2015; n = 567).
Variable HR (95% CI) p Value
Race/color of the patient
Black 2.61 (1.13, 6.02) 0.024
Primary cause of chronic kidney disease
Diabetes Mellitus 3.14 (1.11, 8.81) 0.029
Therapeutic regimen
Cyclosporine + Azathioprine 1.0
Cyclosporine 1.35 (0.37, 4.92) 0.647
Cyclosporine + Mycophenolate 2.14 (0.97, 4.67) 0.058
Cyclosporine + Sirolimus NA
Cyclosporine + Everolimus NA
Tacrolimus + Azathioprine 1.02 ( 0.40, 2.56) 0.967
Tacrolimus 3.93 (0.86, 18.05) 0.077
Tacrolimus + Mycophenolate 2.17 (1.02, 2.41) 0.028
Tacrolimus + Sirolimus 4.63 (1.007, 21.26) 0.050
Tacrolimus + Everolimus NA
NA: not possible to estimate due to small numbers; HR: hazard ratio; CI: confidence interval.
Analysis of the residues demonstrated that the multivariable models showed good adequacy
according to Schoenfeld, with an average close to zero and no violation of the homoscedasticity assumption.
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3.3. Sensitivity Analysis
In the death censored analysis, the overall survival at 15 years was 78.2% (95% CI = 67.4 to 90.6).
Patients in the cyclosporine group had a survival of 87.1% (95% CI = 80.7 to 94.1) while those in the
tacrolimus group had a survival of 70.3% (95% CI = 52.7 to 93.9) (p = 0.04). Regarding the therapeutic
regimens, it was observed that patients prescribed tacrolimus plus mycophenolate had a higher risk of
graft loss (HR = 1.82, p = 0.04), alongside those prescribed tacrolimus plus azathioprine (HR = 1.35,
p = 0.45) and cyclosporine plus mycophenolate (HR = 1.21, p = 0.57) compared with patients who
were prescribed cyclosporine plus azathioprine. In the ‘patient death with a functional graft’ analysis,
no regimen showed a greater advantage than cyclosporine plus azathioprine. Cyclosporine plus
mycophenolate had a higher risk of graft loss (HR = 1.38, p = 0.04) compared with cyclosporine plus
azathioprine, and the different regimens with tacrolimus showed no statistically noticeable difference
(tacrolimus + mycophenolate HR = 0.99, p = 0.84; tacrolimus + azathioprine HR = 1.20, p = 0.35).
4. Discussion
After fifteen years of follow-up, overall renal graft survival was 50.1%. Patients who were
prescribed cyclosporine plus azathioprine had a higher Kaplan–Meier survival rate over the 15 years
compared to patients using tacrolimus plus azathioprine (54.0% vs 37.3%) (Table 2). Overall, comparing
cyclosporine plus azathioprine regimens with all other regimens, our model, adjusted for race
and diabetes mellitus, showed superiority for this regimen versus tacrolimus plus mycophenolate,
with no differences between cyclosporine and the other regimens (Table 5). Adjusting for diabetes is
important since previous studies have reported that patients with diabetes obtain worse post-transplant
results [7,18]. In addition, diabetes is usually related to other cardiovascular factors associated with a
worse prognosis [21,22]. These findings are similar to other published studies and build on our earlier
studies [7,18,23,24].
This compares with Vacher-Coponat et al. (2012) who found that a tacrolimus plus
mycophenolate combinaton is not more efficient than a cyclosporine plus azathioprine combination [25].
The cyclosporine plus mycophenolate regimen, which was the second most prescribed regimen in our
cohort (26.0%), had no significant associated benefit; however, in our final model, this regimen showed
a greater graft loss trend when compared with cyclosporine plus azatioprine (Table 5).
Goldfarb-Rumyantzev et al. [24] reported that a cyclosporine plus mycophenolate regimen is
associated with a lower risk for graft failure compared with tacrolimus plus mycophenolate, which was
comparable to a cyclosporine plus azathioprine regimen, contrasting with the findings of our study.
Wagner et al. in their systematic review reported a 22% reduction in the risk of graft loss due to death
(Relative risk (RR )= 0.78 (95% CI = 0.62 to 0.99)) for patients who were treated with mycophenolate
versus azathioprine in combination with a CNI [10]. We are not sure of the reasons behind the
differences in the findings between the studies; however, this may be related to the type of study and
the limitations inherent to each type of study. In addition, we are aware that black patients need
higher doses of tacrolimus to achieve therapeutic levels due to specific polymorphisms of CYP3A5.
This could, in part, explain the superiority of cyclosporine found in our study [26–28], although we
were not able to evaluate dosage in this study.
In our study, a more advanced age was associated with worse survival, similar to previous
studies [7,18,29,30]. Among the clinical variables, a longer dialysis time before transplant had a negative
influence on graft survival, again similar to other studies [7,18,21,30,31]. Previous studies have shown
that hypertension and cardiovascular disease, nephritis and pyelonephritis, and diabetes mellitus are
the main causes of CKD [7,19,32,33]. The primary diagnoses of CKD, including hypertension, diabetes
mellitus and nephritis, are also associated with an increased risk of graft loss. However, only the
group of patients with a primary diagnosis of diabetes mellitus and hypertension remained in our
final model presenting with a risk of increased graft loss. Miscegenation is a particular demographic
characteristic of the Brazilian population [34]. Whilst we did not have the race and color records for all
patients, since this information only recently became mandatory in the SUS information systems [35],
Int. J. Environ. Res. Public Health 2020, 17, 1974 11 of 15
patients who declared themselves as black presented with a greater risk of loss of graft. These findings
are similar to another study conducted in Brazil [36], which also found worse results in patients who
declared themselves to be black.
We are aware that tacrolimus has typically replaced cyclosporine and mycophenolate has typically
replaced azathioprine in current immunosuppressive regimes [10,37,38]. However, as mentioned,
these two immunosuppressants are currently more expensive in Brazil and their effectiveness has
been the subject of ongoing debate which has been enhanced by our findings. Other important
issues for physicians and authorities to consider when prescribing immunosuppressants include the
fact that 30–60% of recipients develop BK viremia with up to 70% losing their transplanted kidney
from infection [39,40]. Rationally, one can assume that the stronger the immunosuppressive regimen,
the higher the possibility of developing BK viremia. In line with this, Bernnan et al. (2005) [41]
evaluated the effect of a CNI with either mycophenolate or azathioprine on the incidence of BK virus
infections in renal transplant patients. However, they found that the incidence of BK viremia was
equal in patients receiving either a tacrolimus plus mycophenolate or a cyclosporine plus azathioprine
regimen. Consequently, it is difficult to say whether a tacrolimus plus mycophenolate combination is
currently stronger than a cyclosporine plus azathioprine regimen.
During the last few decades, the introduction of new immunosuppressants with new mechanisms
of action has increased the number of options and strategies to avoid rejection, as well as reduce the
side effects associated with tacrolimus and cyclosporine therapies. Sirolimus and everolimus (mTOR)
are among the newer agents [17]. These immunosuppressants are currently recommended as second
treatment line in Brazil [11], which is reflected in their limited use in our study (3.0%). However, there is
ongoing controversy regarding the effectiveness of these combinations [13,14,17,42–44]. Some clinical
trials [45] support the use of everolimus as a standard immunosuppressive drug leading to reduced
exposure to CNI; however, this is not universal. A recent systematic review [45] which compared
mTOR with other immunosuppressants found that everolimus or sirolimus combined with a CNI
prevented kidney transplant failure and rejection as effectively as other immunosuppressants combined
with a CNI in short follow-up periods. However, the risk of viral infections (cytomegalovirus and BK)
was significantly less with mTOR combined with everolimus. We will be exploring this further in the
future in view of the low number of patients prescribed mTOR in our study.
We are aware there are a number of limitations related to the design of this study, and to the source of
information; consequently, the results must be evaluated with caution. Our study was retrospective and
unfortunately did not provide explanations for all the observed associations. Future studies are needed
to confirm identified associations. Administrative records may present incomplete or inconsistent
information, inherent in the retrospective nature of the study. In addition, clinical information that
potentially affects graft survival, such as acute rejection rates, immunological compatibility, ischemia
times, and graft function in the first year after transplantation, was not available in our database.
Another limitation is that cyclosporine, by inhibiting enterohepatic circulation of mycophenolate,
increases the required dose of mycophenolate. However, blood levels of immunosuppressants and
data on adherence to immunosuppressive therapies were also not available. This was despite the
Brazilian Guidelines currently recommending monitoring the level of these immunosuppressants,
and the SUS funds these procedures. Overall, we believe the difference in graft survival between these
regimens can be explained by the difference in nephrotoxicity, associated comorbidity, immunological
risk, or different adverse effect profiles.
Despite it is limitations, we believe the long follow-up period, the representativeness of the sample
(which included practically the entire population of the country undergoing kidney transplantation),
and using immunosuppressants through SUS reflects the real-world scenario in Brazil. Consequently,
we believe our findings to be robust, providing guidance not only to key stakeholders in Brazil, but
also wider audiences.
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5. Conclusions
This retrospective, real-world, nationwide study with a long follow-up period revealed better
long-term outcomes for cyclosporine plus azathioprine versus other regimens for the maintenance of
renal transplants in Brazil. Despite the limitations of the study design and available data, including
clinical features, we believe these findings may give guidance to policy makers and prescribers in
clinical practice, helping them to choose between several possible combinations as first line treatment.
We believe real-world studies such as these will become increasingly important in the future
to help guide decision making given the short term follow-up in most clinical trials, including
those for new immunosuppressants. However, we also suggest that further prospective studies are
conducted to add to our findings and to the overall debate regarding the relative merits of the various
immunosuppressants. In the meantime, protocols and clinical guidelines for renal transplantation
could consider the cyclosporine plus azathioprine regimen as a potential first line option, along
with others.
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